(CLNE) Clean Energy Fuels - Overview
Stock: Natural Gas, CNG, LNG, RNG, Station Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 65.7% |
| Relative Tail Risk | -10.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.22 |
| Alpha | -45.76 |
| Character TTM | |
|---|---|
| Beta | 1.496 |
| Beta Downside | 0.852 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.89% |
| CAGR/Max DD | -0.30 |
Description: CLNE Clean Energy Fuels December 28, 2025
Clean Energy Fuels Corp. (NASDAQ: CLNE) supplies natural-gas-based alternative fuels-renewable natural gas (RNG), compressed natural gas (CNG) and liquefied natural gas (LNG)-to medium- and heavy-duty vehicle fleets across the United States and Canada. In addition to fuel sales, the company designs, builds, operates and maintains both public and private fueling stations, and it sells compressors and related equipment used in RNG production and fueling infrastructure.
Key operating metrics that illustrate CLNE’s market position include roughly 1.2 billion cubic feet of RNG sold in 2023 (≈ 5 % of U.S. RNG volume) and a fleet-service base of over 30,000 vehicles, spanning trucking, airports, refuse, transit, industrial and government customers. The firm’s revenue is heavily tied to policy incentives: Renewable Identification Numbers (RINs) and Low-Carbon Fuel Standard (LCFS) credits currently account for about 30 % of total earnings, and any tightening of federal or state carbon-reduction mandates is a primary growth catalyst. Capital-intensive projects-particularly dairy-derived RNG plants-drive cash-flow volatility, with 2023 capex of ≈ $150 million largely funded through a mix of debt and equity.
For a deeper, data-driven view of CLNE’s valuation dynamics and credit-incentive exposure, you may find ValueRay’s analytical dashboard useful.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -209.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 4.10 > 1.0 |
| NWC/Revenue: 60.81% < 20% (prev 72.06%; Δ -11.24% < -1%) |
| CFO/TA 0.08 > 3% & CFO 94.3m > Net Income -209.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (219.3m) vs 12m ago -1.85% < -2% |
| Gross Margin: 4.79% > 18% (prev 0.19%; Δ 460.4% > 0.5%) |
| Asset Turnover: 35.63% > 50% (prev 33.22%; Δ 2.41% > 0%) |
| Interest Coverage Ratio: -5.75 > 6 (EBITDA TTM -81.4m / Interest Expense TTM 31.2m) |
Altman Z'' -5.32
| A: 0.23 (Total Current Assets 409.1m - Total Current Liabilities 152.3m) / Total Assets 1.13b |
| B: -1.06 (Retained Earnings -1.19b / Total Assets 1.13b) |
| C: -0.15 (EBIT TTM -179.3m / Avg Total Assets 1.18b) |
| D: -2.24 (Book Value of Equity -1.19b / Total Liabilities 534.1m) |
| Altman-Z'' Score: -5.32 = D |
Beneish M -0.74
| DSRI: 0.88 (Receivables 110.4m/122.7m, Revenue 422.2m/413.4m) |
| GMI: 3.96 (GM 4.79% / 18.96%) |
| AQI: 0.94 (AQ_t 0.27 / AQ_t-1 0.28) |
| SGI: 1.02 (Revenue 422.2m / 413.4m) |
| TATA: -0.27 (NI -209.2m - CFO 94.3m) / TA 1.13b) |
| Beneish M-Score: -0.74 (Cap -4..+1) = D |
What is the price of CLNE shares?
Over the past week, the price has changed by +12.00%, over one month by +15.07%, over three months by +7.69% and over the past year by -29.41%.
Is CLNE a buy, sell or hold?
- StrongBuy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CLNE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.7 | 86.9% |
| Analysts Target Price | 4.7 | 86.9% |
| ValueRay Target Price | 2 | -20.2% |
CLNE Fundamental Data Overview February 05, 2026
P/S = 1.2321
P/B = 0.8432
P/EG = 2.42
Revenue TTM = 422.2m USD
EBIT TTM = -179.3m USD
EBITDA TTM = -81.4m USD
Long Term Debt = 284.2m USD (from longTermDebt, last quarter)
Short Term Debt = 9.90m USD (from shortTermDebt, last quarter)
Debt = 381.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 198.6m USD (from netDebt column, last quarter)
Enterprise Value = 667.0m USD (519.7m + Debt 381.6m - CCE 234.3m)
Interest Coverage Ratio = -5.75 (Ebit TTM -179.3m / Interest Expense TTM 31.2m)
EV/FCF = 18.76x (Enterprise Value 667.0m / FCF TTM 35.6m)
FCF Yield = 5.33% (FCF TTM 35.6m / Enterprise Value 667.0m)
FCF Margin = 8.42% (FCF TTM 35.6m / Revenue TTM 422.2m)
Net Margin = -49.55% (Net Income TTM -209.2m / Revenue TTM 422.2m)
Gross Margin = 4.79% ((Revenue TTM 422.2m - Cost of Revenue TTM 401.9m) / Revenue TTM)
Gross Margin QoQ = 12.17% (prev 17.76%)
Tobins Q-Ratio = 0.59 (Enterprise Value 667.0m / Total Assets 1.13b)
Interest Expense / Debt = 2.04% (Interest Expense 7.78m / Debt 381.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -141.6m (EBIT -179.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.69 (Total Current Assets 409.1m / Total Current Liabilities 152.3m)
Debt / Equity = 0.65 (Debt 381.6m / totalStockholderEquity, last quarter 585.2m)
Debt / EBITDA = -2.44 (negative EBITDA) (Net Debt 198.6m / EBITDA -81.4m)
Debt / FCF = 5.59 (Net Debt 198.6m / FCF TTM 35.6m)
Total Stockholder Equity = 621.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -17.66% (Net Income -209.2m / Total Assets 1.13b)
RoE = -33.66% (Net Income TTM -209.2m / Total Stockholder Equity 621.5m)
RoCE = -19.79% (EBIT -179.3m / Capital Employed (Equity 621.5m + L.T.Debt 284.2m))
RoIC = -15.80% (negative operating profit) (NOPAT -141.6m / Invested Capital 896.3m)
WACC = 7.27% (E(519.7m)/V(901.3m) * Re(11.43%) + D(381.6m)/V(901.3m) * Rd(2.04%) * (1-Tc(0.21)))
Discount Rate = 11.43% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.84%
[DCF Debug] Terminal Value 73.67% ; FCFF base≈35.6m ; Y1≈23.3m ; Y5≈10.7m
Fair Price DCF = 0.19 (EV 239.5m - Net Debt 198.6m = Equity 40.9m / Shares 219.3m; r=7.27% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 12.28 | EPS CAGR: 17.40% | SUE: 0.86 | # QB: 1
Revenue Correlation: 17.89 | Revenue CAGR: 3.99% | SUE: 0.91 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.03 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.04 | Chg30d=-0.004 | Revisions Net=-1 | Growth EPS=-53.7% | Growth Revenue=+1.7%